Tuberculosis cases are up among kids in Europe and Central Asia, health authorities warn
Cases of tuberculosis (TB), the world's deadliest infectious disease, are up nearly 10 per cent year-over-year among children in Europe and Central Asia, according to a new report from international health agencies.
The data, which is from 2023, indicates that the European region is still grappling with the spillover effects of the COVID-19 pandemic, according to the report from the European Centre for Disease Prevention and Control (ECDC) and the World Health Organization's (WHO) Europe team.
And it comes as health officials warn that cuts to global aid could lead to a resurgence of TB worldwide.
In 2023, more than 172,000 people in the European region either got TB or had a relapse of the disease, similar to levels reported in 2022, the analysis shows. While TB deaths declined, they fell at a much slower rate than before the COVID-19 crisis.
Related
Global aid cuts are 'crippling' the fight against the world's deadliest infectious disease, WHO says
That suggests many infected people went undiagnosed and untreated when the pandemic disrupted medical services, and that the consequences are now becoming apparent, the report said.
The toll on children also appears to be growing, with about 7,500 TB cases among kids under age 15 in the European region in 2023 – a 9.6 per cent increase from the year before, the report found.
More than 2,400 of these cases were reported among children under 5, who are at higher risk of serious illness and death.
'The current TB burden and the worrying rise in children with TB serves as a reminder that progress against this preventable and curable disease remains fragile," Dr Hans Kluge, the WHO Europe director, said in a statement.
The findings indicate that TB is continuing to spread across Europe and that 'immediate' public health efforts should be put in place to get the disease in check, the report said.
TB is caused by a bacterial infection that mainly affects the lungs but can also spread to other organs. Most people who are infected do not go on to develop the disease, but if they do, it can be dangerous, killing about 1.25 million people per year.
It also coincides with other critical health problems. In the European region, 15.4 per cent of people with new or reactivated TB also have HIV, which can progress to AIDS if left untreated, the report said.
Related
Public programme to give poor people cash reduced tuberculosis cases and deaths, study finds
TB primarily affects people living in poverty. It can be difficult to manage for a host of reasons, including delays in getting a diagnosis, whether patients take their medication on time, and a lack of access to the right treatments.
Patients must take TB medication daily for up to six months in order for it to be effective.
Stopping treatment early can allow the bacteria to become resistant to drugs, making the disease harder to treat and allowing infections to spread.
First-line drugs worked for 75.5 per cent of patients in the European region, the analysis shows. For those with multi-drug resistant TB, medicines eventually worked for 59.7 per cent.
Looking only at the European Union, Iceland, Liechtenstein, and Norway, health authorities said they do not know whether one in five children with TB actually completed treatment.
Related
Antibiotic-resistant superbugs could kill 39 million people by 2050, researchers warn
'With the rise of drug-resistant TB, the cost of inaction today will be paid by us all tomorrow,' ECDC director Dr Pamela Rendi-Wagner said in a statement.
Last week, the WHO warned that cuts to global aid are already undermining progress to eliminate the disease in 27 countries, mostly in Africa, Southeast Asia, and the Western Pacific. In nine countries, people are struggling to get TB medicine.
But Kluge said that TB programmes in Europe and Central Asia could also be affected by the cuts.
Across the region, Russia had the most cases in 2023, followed by Ukraine, Uzbekistan, Kazakhstan, Turkey, and Romania.
The cuts mean 'TB transmission may go unnoticed, further fuelling the rise in hard-to-treat strains,' Kluge said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
28 minutes ago
- Yahoo
No drug price pledges in talks with US government, Pfizer CEO says
STORY: Pfizer CEO Albert Bourla said Monday that he and other drug companies met with the Trump administration to discuss lowering U.S. drug prices but no commitments have been made. He made the comments at a Goldman Sachs healthcare conference. Last month President Trump issued an executive order directing drugmakers to lower the prices of their medicines to align with what other countries pay. According to the order, the administration was to set "Most Favored Nation" price targets within 30 days. The Department of Health and Human Services has said it expects drugmakers in the U.S. to set prices for their products at the lowest price paid by other high-income countries. Bourla said he didn't know what the companies would hear in 30 days and added the meetings with the administration so far were cordial but (quote) "not digging into the substance." It is unclear what mechanism the U.S. government will use to lower drug prices - analysts and legal experts have said the policy will be difficult to implement. Bourla said he is hopeful that, given U.S. pressure on European countries to pay more, prices there could increase. He said that if the U.S. resorts to price controls, Pfizer could consider not making drugs available for government reimbursement in some countries if prices don't increase there. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
3 Healthcare Stocks Skating on Thin Ice
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But speed bumps such as inventory destockings have persisted in the wake of COVID-19, and over the past six months, the industry has pulled back by 12.3%. This performance was noticeably worse than the S&P 500's 1.9% fall. Investors should tread carefully as the influx of venture capital has also ushered in a new wave of competition. Taking that into account, here are three healthcare stocks we're swiping left on. Market Cap: $48.91 billion With a history dating back to 1897 and a presence in virtually every hospital around the globe, Becton Dickinson (NYSE:BDX) develops and manufactures medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions and professionals worldwide. Why Do We Think Twice About BDX? Annual sales growth of 4.1% over the last five years lagged behind its healthcare peers as its large revenue base made it difficult to generate incremental demand 10.5 percentage point decline in its free cash flow margin over the last five years reflects the company's increased investments to defend its market position Below-average returns on capital indicate management struggled to find compelling investment opportunities BD is trading at $170.95 per share, or 11.4x forward P/E. If you're considering BDX for your portfolio, see our FREE research report to learn more. Market Cap: $8.28 billion With a unique business model combining end-of-life care and household services, Chemed (NYSE:CHE) operates two distinct businesses: VITAS, which provides hospice care for terminally ill patients, and Roto-Rooter, which offers plumbing and water restoration services. Why Does CHE Fall Short? 4.6% annual revenue growth over the last five years was slower than its healthcare peers Capital intensity has ramped up over the last five years as its free cash flow margin decreased by 8.9 percentage points Waning returns on capital imply its previous profit engines are losing steam At $568.39 per share, Chemed trades at 22x forward P/E. Read our free research report to see why you should think twice about including CHE in your portfolio, it's free. Market Cap: $10.73 billion Formerly known as PerkinElmer until its rebranding in 2023, Revvity (NYSE:RVTY) provides health science technologies and services that support the complete workflow from discovery to development and diagnosis to cure. Why Is RVTY Risky? Organic sales performance over the past two years indicates the company may need to make strategic adjustments or rely on M&A to catalyze faster growth Day-to-day expenses have swelled relative to revenue over the last five years as its adjusted operating margin fell by 8.8 percentage points Eroding returns on capital suggest its historical profit centers are aging Revvity's stock price of $91.03 implies a valuation ratio of 17.6x forward P/E. Check out our free in-depth research report to learn more about why RVTY doesn't pass our bar. Donald Trump's victory in the 2024 U.S. Presidential Election sent major indices to all-time highs, but stocks have retraced as investors debate the health of the economy and the potential impact of tariffs. While this leaves much uncertainty around 2025, a few companies are poised for long-term gains regardless of the political or macroeconomic climate, like our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today for free. Sign in to access your portfolio
Yahoo
2 hours ago
- Yahoo
Arkansas ranks 45th for child well-being in national report, despite modest gains
LITTLE ROCK, Ark. – Arkansas ranks 45th in the nation for overall child well-being, according to the 2025 KIDS COUNT Data Book released Monday by the Annie E. Casey Foundation. The annual report evaluates how children are doing across all 50 states in four areas: economic well-being, education, health, and family and community. 6-year-old Dennis Martin still missing after disappearing in Smokies in 1969 Though Arkansas has made some gains since the COVID-19 pandemic, the state continues to fall behind on most indicators compared to national averages. One area of progress is child poverty. The number of Arkansas children living in poverty has dropped by 7,000 since 2019. Still, 21% of the state's children remain in poverty, which is higher than the national rate of 16%. 'This report shows that while there has been some improvement, too many of our children are still being left behind,' said Keesa Smith-Brantley, executive director of Arkansas Advocates for Children and Families. 'We can't be satisfied with small gains when the overall trends remain troubling.' Racial disparities remain a serious issue. Officials said Black children in Arkansas face a poverty rate of 43%. Children of two or more races have a poverty rate of 21%, while 19% of Hispanic or Latino children live in poverty. Non-Hispanic White children have the lowest poverty rate at 15%. Ohio girl with brain injury from flu complications returns home In addition to being ranked 44th for child poverty, Arkansas is in the bottom 10 states on the following indicators: Teens ages 16-19 not attending school and not working 8th graders below proficient on math level Low-birthweight babies Child and teen deaths Teens ages 10-17 who are overweight or obese Children in single-parent families Children living in high-poverty areas Teen birth rate 'If you look at the data, teens are where we're falling further behind,' Smith-Brantley said. 'We're seeing more teens out of school and unemployed, and more who are overweight or obese. These are outcomes tied directly to the decisions our leaders are or aren't making.' For more information, visit Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
